Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for moderate traumatic brain injury
IRCT20230627058603N2Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in traumatic brain injury (TBI) comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Improvement in level of alertness. Started Dec 2023; status: completed.
02
Drugs
rosuvastatin
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20230627058603N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230627058603N2.